Effect of Rosiglitazone Combined with Liraglutide in the Treatment of Young Patients with Type 2 Diabetes Complicated with Nonalcoholic Fatty Liver
Objective:To investigate the effect of Rosiglitazone combined with Liraglutide in the treatment of young patients with type 2 diabetes complicated with nonalcoholic fatty liver.Method:A total of 60 young patients with type 2 diabetes complicated with nonalcoholic fatty liver who treated in Longhua District People's Hospital of Shenzhen City from January to December 2023 were selected as the study objects,and they were divided into two groups by random number table method,with 30 cases in each group.The control group was treated with Rosiglitazone,and the study group was treated with Rosiglitazone combined with Liraglutide.The clinical efficacy,blood glucose,glycosylated hemoglobin,triglyceride,body mass index,liver function and incidence of adverse reactions were compared between two groups.Result:The total clinical effective rate of the study group was 93.33%,which was higher than 70.00%of the control group,and the difference was statistically significant(P＜0.05).After treatment,the levels of blood glucose,glycosylated hemoglobin,triglyceride,body mass index in two groups were lower than those before treatment,and those in the study group were lower than those in the control group,the differences were statistically significant(P＜0.05).After treatment,γ-glutamyl transferase(GGT),alanine transaminase(ALT),aspartate transaminase(AST)levels in two groups were lower than those before treatment,and those in the study group were lower than those in the control group,the differences were statistically significant(P＜0.05).The incidence of adverse reactions in the study group was 10.00%,which was lower than 6.67%in the control group,but there was no statistical significance between two groups(P＞0.05).Conclusion:Rosiglitazone combined with Liraglutide in the treatment of young patients with type 2 diabetes complicated with nonalcoholic fatty liver can reduce blood glucose,blood lipid,body mass index,improve liver function,and do not significantly increase adverse reactions.
Type 2 diabetesRosiglitazoneLiraglutideNonalcoholic fatty liver diseaseBlood glucoseLiver function
万方数据
维普
